Aridis Pharmaceuticals Inc. (ARDS)
Stock Price:
$6.50 USD
0.09 (1.40%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
58.00M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-28.12M |
| Shares Out |
8.92M |
| EPS (ttm) |
-3.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$6.50 |
| Previous Close |
$6.41 |
| Change ($) |
0.09 |
| Change (%) |
1.40% |
| Day's Open |
6.41 |
| Day's Range |
6.23 - 6.95 |
| Day's Volume |
9,284 |
| 52-Week Range |
3.80 - 12.40 |
More Stats
| Market Cap |
58.00M |
| Enterprise Value |
41.68M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
8.92M |
| Float |
5.20M |
| EPS (basic) |
-3.25 |
| EPS (diluted) |
-3.25 |
| FCF / Share |
-0.56 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
27,903 |
| Short Ratio |
3.01 |
| Short % of Float |
0.39% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
20.98 |
| Revenue |
n/a |
| Operating Income |
-27.91M |
| Net Income |
-28.12M |
| Free Cash Flow |
-4.99M |
| Net Cash |
16.32M |
| Net Cash / Share |
1.83 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-77.08% |
| ROE |
-344.38% |
| ROIC |
735.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$18.60*
(186.15% upside)
Low
11.0
Current: 6.50
High
25.0
Target: 18.60
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 1.02 | 2.76 | 0.86 | 2.27 |
| Revenue Growth | -62.93% | 220.58% | -62.1% | - |
| Gross Profit | 1.02 | 2.76 | 0.86 | 0.34 |
| Operating Income | -29.09 | -24.12 | -19.74 | -7.88 |
| Net Income | -29.68 | -22.11 | -24.66 | -8.42 |
| Shares Outstanding | 8.46 | 3.15 | 0.17 | 0.17 |
| Earnings Per Share | -3.51 | -7.45 | -148.20 | -50.62 |
| Operating Cash Flow | -8.16 | -24.27 | -17.56 | -6.09 |
| Capital Expenditures | -0.17 | -0.68 | -0.70 | -0.02 |
| Free Cash Flow | -8.33 | -24.95 | -18.26 | -6.11 |
| Cash & Equivalents | 20.90 | 24.24 | 25.10 | 22.29 |
| Net Cash / Debt | 20.90 | 24.24 | 25.10 | 22.29 |
| Assets | 27.97 | 31.61 | 26.48 | 22.54 |
| Liabilities | 24.33 | 5.30 | 15.04 | 8.76 |
| Book Value | 3.64 | 26.31 | -62.77 | -45.12 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aridis Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
25 |
| CEO |
Vu L. Truong |
Stock Information
| Ticker Symbol |
ARDS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARDS |
| IPO Date |
August 10, 2018 |
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.